The new Minister of Health of The Netherlands, Bruno Bruins, has put the pharmaceutical industry on notice announcing on 22 November he planned to “change the rules of the game” to tackle what he called “absurd” medicines pricing. He told the Dutch parliament that he plans to “extensively explore” the use of compulsory licensing of patents of medicines that are too expensive.
Compulsory licensing lifts the monopoly effect of a patent by allowing others to produce generic versions. The Dutch patent law provides for compulsory licensing, including for reasons of public interest, which presumably covers addressing “absurd pricing” of needed medicines.
EU medicines regulations may stand in the way of the Minister’s plans when data exclusivity rules prevent the registration of the generic. He will also explore if he can authorise pharmacists to prepare medicines al lower cost for individual patients.
The minister is following the recommendations of the Netherlands Council for Public Health and Society, an official government advisory body, which published its report on 8 November. The Council’s report outlines a number of actions the Dutch government can take to immediately address high drug pricing, including the use of compulsory licensing to strengthen the government’s position in price negotiations.
The new Dutch government and the opposition seem to be aligned on the need to take firm action to ensure access to new and expensive medicines. On 21 November three opposition parties presented their report on the pharmaceutical industry in which they recommend a series of measures aimed at lowering the price of medicines: a ban on the endless extension (evergreening) of patents; a National Medicines Research Fund, for independent medical research. Research priorities are determined by the government and not by the pharmaceutical companies; preventing conflicts of interest between doctor and big pharma by restricting aggressive marketing and actively enforcing the advertising ban; the use of compulsory licenses as pharmaceutical companies refuse to lower absurdly high prices; adaptation of the competition law and stricter supervision to better combat abuse of power; and putting an end to none transparent price negotiation.
Embracing the flexibility in patent law to address high medicines pricing by a high-income country government signals new a development in Europe. Low and middle-income countries have used compulsory licensing regularly; for example, to gain access to essential HIV medicines. Only recently, Malaysia issued a compulsory license to be able to purchase generic sofosbuvir, a direct-acting antiviral medicine to treat hepatitis C. With this move, Malaysia reduced the drug cost from $70,000 to $300 per treatment according to the Drugs for Neglected Diseases initiative. In the past the use of compulsory licensing by developing countries was often met with opposition from the US and the EU.Medicines Law and Polity material Netherlands Council of Public Health and Society report